914349-79-4 Usage
Description
(5-BROMOPYRAZIN-2-YL)CARBAMIC ACID TERT-BUTYL ESTER is an organic compound that serves as a crucial intermediate in both organic synthesis and pharmaceutical development. It is primarily utilized in laboratory research and development processes, as well as in chemical production.
Uses
Used in Organic Synthesis:
(5-BROMOPYRAZIN-2-YL)CARBAMIC ACID TERT-BUTYL ESTER is used as an organic synthesis intermediate for the creation of various complex organic molecules. Its unique structure allows it to be a versatile building block in the synthesis of a wide range of compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (5-BROMOPYRAZIN-2-YL)CARBAMIC ACID TERT-BUTYL ESTER is used as a pharmaceutical intermediate. It plays a significant role in the development of new drugs, contributing to the advancement of medicinal chemistry and the discovery of novel therapeutic agents.
Used in Laboratory Research and Development:
(5-BROMOPYRAZIN-2-YL)CARBAMIC ACID TERT-BUTYL ESTER is employed in laboratory settings for research and development purposes. It aids scientists in understanding the properties and potential applications of this compound, paving the way for future innovations in both organic synthesis and pharmaceuticals.
Used in Chemical Production Process:
(5-BROMOPYRAZIN-2-YL)CARBAMIC ACID TERT-BUTYL ESTER is also utilized in the chemical production process, where it serves as a key component in the manufacturing of various chemical products. Its presence in the production process ensures the synthesis of high-quality end products that meet industry standards.
Synthesis
At 0 ℃, to 5-bromopyrazine-2-amine (5736.8mg, 32.97mmol) in CH2Cl2 (80mL) solution was added 4-DMAP (403.2mg, 3.30mmol); then at 0 ℃ drop two A solution of di-tert-butyl carbonate (11.4ml, 3.30mmol) in CH2Cl2; the mixture was stirred at room temperature; after the completion of the reaction was monitored by TLC, the solution was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo; the crude product was chromatographed on a silica gel column Method, purified with ethyl acetate/petroleum ether (1/2) to obtain a white solid product (7250.4 mg, yield 80.2%).
Check Digit Verification of cas no
The CAS Registry Mumber 914349-79-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,4,3,4 and 9 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 914349-79:
(8*9)+(7*1)+(6*4)+(5*3)+(4*4)+(3*9)+(2*7)+(1*9)=184
184 % 10 = 4
So 914349-79-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H12BrN3O2/c1-9(2,3)15-8(14)13-7-5-11-6(10)4-12-7/h4-5H,1-3H3,(H,12,13,14)
914349-79-4Relevant articles and documents
Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors
Dong, Ru,Zhang, Cheng,Wang, Chao,Zhou, Xin,Li, Wen,Zhang, Jin-Yang,Wang, Min,Xu, Yong,Sun, Li-Ping
, (2022/01/11)
Bromodomain-containing Protein 4 (BRD4), an ‘epigenetic reader’, regulates chromatin structure and gene expression via recognizing and binding acetylated lysine in histones. BRD4 has become a therapeutic target for cancers because it promotes the expression of the tumor genes, such as c-Myc, NF-κB, and Bcl-2. In this study, a new series of 3-methyl-1H-indazole derivatives were designed via virtual screening and structure-based optimization. All compounds were synthesized and evaluated for their inhibitory activities to BRD4-BD1 and their antiproliferative effects in cancer cell lines. Among them, several compounds (such as 9d, 9u and 9w) exhibited strong BRD4-BD1 affinities and inhibition activities, and potently suppressed MV4;11 cancer cell line proliferation. Among them, compound 9d showed excellent selectivity for BRD4 and effectively suppressed c-Myc, the downstream protein of BRD4. This study provided new lead compounds for further biological evaluation on BRD4.
LPA RECEPTOR ANTAGONISTS AND USES THEREOF
-
Paragraph 0355, (2021/12/31)
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
